Brokerages Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $20.40

Telix Pharmaceuticals Limited (NASDAQ:TLX) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $20.40.

Several brokerages recently issued reports on TLX. Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a report on Friday, July 17th. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st.

Telix Pharmaceuticals Stock Up 1.7%

NASDAQ:TLX opened at $11.94 on Thursday. The stock has a 50 day moving average of $11.21 and a 200-day moving average of $9.96. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $12.48. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of TLX. Russell Investments Group Ltd. acquired a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at $975,000. Jane Street Group LLC acquired a new position in Telix Pharmaceuticals in the second quarter worth approximately $564,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the second quarter valued at $213,000. Rhumbline Advisers lifted its position in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Telix Pharmaceuticals during the 3rd quarter valued at $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.